Catalyst Crew Technologies Corp. has filed a Form 8-K with the U.S. Securities and Exchange Commission disclosing a material change in its business direction and corporate strategy. The company is transitioning from its prior business focus to pursue operations as a development-stage artificial intelligence-enabled healthcare technology company, with an initial focus on Latin America and other emerging markets. A copy of the company's Form 8-K is available for review on the SEC's EDGAR database at https://www.sec.gov/Archives/edgar/data/1840439/000119312526068375/d95198d8k.htm.
The company's anticipated areas of focus include development of AI-driven healthcare software platforms, telehealth and remote patient monitoring technologies, clinical data analytics and interoperability systems, healthcare workflow and administrative automation solutions, and strategic acquisitions and partnerships within the healthcare technology sector. The company remains in the development stage of this strategic transition and is actively implementing its new plan of operations. There can be no assurance that the company will successfully implement its new business plan, secure financing, complete acquisitions, enter into definitive agreements, or generate revenues.
In connection with its revised strategic direction, the company intends to change its corporate name to LataMed AI Corp. The proposed name change is expected to be effected through the filing of Articles of Amendment with the State of Nevada and is subject to required corporate approvals. Additionally, the company intends to submit a Company Related Action Notification Form and supporting documentation to the Financial Industry Regulatory Authority, requesting review and processing of both the corporate name change and a corresponding ticker symbol change.
The filing of Articles of Amendment and submission to FINRA are procedural steps in the corporate action process. Neither the corporate name change for marketplace purposes nor any ticker symbol change will become effective until FINRA has completed its review and announces the effective date of the corporate action. There can be no assurance regarding the timing of FINRA's review or that FINRA will approve the requested corporate action. The company will issue a subsequent press release upon confirmation of the effective date assigned by FINRA.
The company intends to continue meeting its reporting obligations under the Securities Exchange Act of 1934 and will provide updated disclosures through filings with the SEC and through OTC Markets Group, as applicable. The company is in the process of developing a new corporate website that will reflect its updated business direction and branding and expects to provide additional updates as they become available.
This strategic pivot represents a significant shift toward addressing healthcare technology gaps in emerging markets, particularly Latin America, where digital health infrastructure remains underdeveloped. The move positions the company to potentially capitalize on growing demand for telehealth, remote monitoring, and AI-driven healthcare solutions in regions with expanding healthcare needs. However, as a development-stage enterprise, the company has not generated revenues from its newly announced business direction, and successful implementation depends on multiple factors including regulatory approvals, financing, and market acceptance.
